This name describes two separate synthetic peptides, CJC-1295 and ipamorelin, sold together. Neither peptide is FDA-approved, no combination of the two has been approved, and no approved medicine in the United States contains either one.
The blend is a marketing combination, not a product that was developed and tested as a single drug. We found no published clinical trial of the two peptides used together.
The idea behind the combination is that the two peptides act on the pituitary through different receptors. That rationale comes from how each works on its own, not from any trial of the blend.
CJC-1295: in two small randomized, placebo-controlled trials in healthy adults published in 2006, a single administration of the DAC version raised average growth hormone levels 2- to 10-fold for 6 days or more, and IGF-1 levels 1.5- to 3-fold. These early studies measured hormone levels, not health outcomes, and CJC-1295 was never developed into an approved medicine.
Ipamorelin: its main human test was a phase 2 trial, published in 2014, in 114 adults recovering from bowel surgery. Median time to the first tolerated meal was 25.3 hours with IV ipamorelin and 32.6 hours with placebo, a difference that was not statistically significant. Ipamorelin has not been approved for any use.
Current status: Not FDA-approved.
The FDA's Pharmacy Compounding Advisory Committee has reviewed both peptides for the 503A Bulks List, the list of bulk substances pharmacies may use for compounding. On October 29, 2024, it voted against ipamorelin, which was reviewed for growth hormone deficiency and postoperative ileus, with 0 votes in favor, 12 against and 1 abstention. On December 4, 2024, it voted against every form of CJC-1295 it reviewed, including the DAC versions. FDA staff had recommended against both, and neither peptide is on the 503A Bulks List.
Products sold online as research chemicals or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents, purity or quality.
There is no FDA label for either peptide. For CJC-1295, the FDA has cited a possible risk of immunogenicity (an unwanted immune response), peptide impurities, and reported serious adverse events including increased heart rate and a widening of blood vessels throughout the body. The advisory committee members who voted against ipamorelin pointed to a lack of information supporting its safety and effectiveness. The safety of combining the two has not been studied.
Both peptides are named on the World Anti-Doping Agency (WADA) 2026 Prohibited List under class S2: CJC-1295 as a GHRH analog and ipamorelin as a growth hormone secretagogue. Both are prohibited at all times, in and out of competition.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply this blend, and we do not point readers to anyone who does.
For personal medical questions, including questions about this blend, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide. Each ingredient has its own profile: CJC-1295 and ipamorelin. A related GHRH analog is sermorelin. We compare the individual compounds in tesamorelin vs sermorelin vs ipamorelin.